<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trazodone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet"/></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trazodone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Trazodone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11115" href="/d/html/11115.html" rel="external">see "Trazodone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12855" href="/d/html/12855.html" rel="external">see "Trazodone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708898"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behaviors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Trazodone is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868482"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-TraZODone;</li>
<li>APO-TraZODone D;</li>
<li>JAMP-Trazodone;</li>
<li>PMS-TraZODone;</li>
<li>TEVA-TraZODone;</li>
<li>TraZODone-100;</li>
<li>TraZODone-150;</li>
<li>TraZODone-50</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F230317"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant, Serotonin Reuptake Inhibitor/Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F230284"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8e8c293-a11f-4930-811b-474d595c5fe9">Aggressive or agitated behavior associated with dementia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aggressive or agitated behavior associated with dementia (alternative agent) (off-label use)</b>: Based on limited data: <b>Oral:</b> Initial: 25 to 50 mg once daily at bedtime; may increase dose gradually based on response and tolerability up to 300 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18340692','lexi-content-ref-15178953','lexi-content-ref-9169246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18340692','lexi-content-ref-15178953','lexi-content-ref-9169246'])">Ref</a></span>). Some experts target doses in the lower end of the dosing range, rarely using doses as high as 100 to 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Press.2019','lexi-content-ref-21288069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Press.2019','lexi-content-ref-21288069'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3cc2398c-8a01-4325-9ce5-54c75a0644c1">Insomnia, sleep onset and sleep maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia, sleep onset and sleep maintenance (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Limit long-term use (&gt;4 weeks) to cases for which nonpharmacologic treatments are not available or not effective and benefits are felt to outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27136449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27136449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Usual dose: 50 mg to 100 mg at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29680424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29680424'])">Ref</a></span>). <b>Note:</b> Lower initial doses of 12.5 to 50 mg at bedtime may be considered (eg, in palliative care patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24659320','lexi-content-ref-22777411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24659320','lexi-content-ref-22777411'])">Ref</a></span>). May consider increasing dose based on response and tolerability up to 200 mg at bedtime (eg, in patients with substance use disorder) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18616688','lexi-content-ref-12920414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18616688','lexi-content-ref-12920414'])">Ref</a></span>). In patients with substance use disorder, trazodone may be preferred due to its low abuse potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2006']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2006'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Insomnia in patients with depression </i>(as adjunct to other appropriate antidepressant treatment [eg SSRI]): <b>Oral:</b> Usual dose: 50 to 300 mg at bedtime. Doses up to 600 mg/day have been evaluated; however, evidence of greater benefit is uncertain and adverse effects may be increased (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15816789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15816789'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (alternative agent):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial: 50 mg twice daily; may increase in increments of 50 mg/day every 3 to 7 days to a target dose of 75 to 150 mg twice daily. Thereafter may further increase by 50 to 100 mg/day every 2 to 4 weeks based on response and tolerability; usual dosage range 200 to 400 mg/day; maximum 600 mg/day. <b>Note:</b> Adverse effects are increased with doses &gt;400 mg/day and are not recommended in patients with cardiovascular disease; sedative effects may be better tolerated by dividing the daily dose to give a smaller dose in daytime and larger dose before bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer’s labeling: Dosing in prescribing information may not reflect current clinical practice. Initial: 150 mg/day in divided doses; maximum dose: 600 mg/day (inpatients); 400 mg/day (outpatients).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i>Due to its short half-life, withdrawal symptoms are likely with abrupt discontinuation. When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2018.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2018.1'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (Shelton 2001). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching antidepressants:</b></i> Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018.2','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018.2','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of trazodone.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing trazodone and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990339"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Mild to severe impairment: No dosage adjustment necessary; titrate with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-743386','lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-743386','lexi-content-ref-22859791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, Intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6746584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6746584'])">Ref</a></span>); no dosage adjustment necessary; titrate with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary; titrate with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987696"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note<i>: </i></b>The effects of trazodone in patients with hepatic impairment have not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial dose or dose titration in patients with preexisting liver cirrhosis: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A through C: </b>Initial: Use the lowest recommended indication-specific dose; may gradually titrate based on response and tolerability with frequent monitoring for dose-related adverse effects (eg, oversedation) that may appear similar or additive to the presentation of hepatic encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25175904','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25175904','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Do not exceed the usual indication-specific maximum recommended dose or 400 mg/day, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg progression from Child-Turcotte-Pugh Class A to B): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to new Child-Turcotte-Pugh class A through C: </b></p>
<p style="text-indent:-2em;margin-left:4em;">If underlying oversedation/encephalopathy is <b>
<i>not</i></b> present: No dosage adjustment necessary; monitor frequently for dose-related adverse effects (eg, oversedation) that may appear similar or additive to the presentation of hepatic encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25175904','lexi-content-ref-19031375','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25175904','lexi-content-ref-19031375','lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">If oversedation/encephalopathy <b>
<i>is</i></b> present: Consider 50% dose reduction weekly until symptoms resolve or stop therapy immediately if it is considered safe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening of hepatic function (eg requiring hospitalization): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A through C:</b> Permanently discontinue therapy if trazodone-induced liver injury is suspected. If trazodone-induced liver injury has been ruled out, may continue trazodone therapy with no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>). However, if trazodone-related adverse effects (eg, oversedation, QT prolongation, orthostasis) and/or new or worsening encephalopathy are observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25175904','lexi-content-ref-19031375','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25175904','lexi-content-ref-19031375','lexi-content-ref-Expert.DOH'])">Ref</a></span>), consider permanent discontinuation of trazodone or use of alternative therapy as appropriate after acute event resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F230285"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (alternative agent): Oral:</b> Initial: 25 to 50 mg at bedtime; may increase in increments of 25 to 50 mg/day every 3 days for inpatients and weekly for outpatients, if tolerated; usual dose: 75 to 150 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Switching antidepressants:</i></b> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F230299"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12855" href="/d/html/12855.html" rel="external">see "Trazodone: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="29cf9b0b-cda1-4b3f-b05f-674417341eb8">Insomnia; sleep disturbances</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia; sleep disturbances:</b> Limited data available; frequently used clinically in children with comorbid neuropsychiatric disorders (eg, autistic spectrum disorders [ASDs], neurogenetic disorders, mood disorders, anxiety disorders, developmental delay with attention-deficit hyperactivity disorder) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31638842','lexi-content-ref-21296553','lexi-content-ref-15843773','lexi-content-ref-20621556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31638842','lexi-content-ref-21296553','lexi-content-ref-15843773','lexi-content-ref-20621556'])">Ref</a></span>). Due to possible risk of QT prolongation, it is suggested to avoid or use with caution in patients with Rett syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31638842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31638842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 18 months to &lt;3 years: Oral: Initial: 1 to 2 mg/kg/dose at bedtime; maximum dose: 25 mg/dose; may increase dose at 2-week intervals in 12.5 to 25 mg increments up to 3 mg/kg/dose once daily at bedtime, not to exceed a maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351','lexi-content-ref-16182678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351','lexi-content-ref-16182678'])">Ref</a></span>). <b>Note:</b> Pharmacokinetic analysis based on simulation reported that the following age-dependent pediatric doses resulted in exposures similar to adult doses of 30 to 150 mg/day: Children 2 to 6 years: 0.35 to 1.6 mg/kg/day; experiential data are needed to fully assess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31808613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31808613'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to 5 years: Oral: Initial: 1 to 2 mg/kg/dose at bedtime; maximum dose: 50 mg/dose; may increase dose at 2-week intervals in 12.5 to 25 mg increments up to 3 mg/kg/dose once daily at bedtime, not to exceed a maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26799351','lexi-content-ref-16182678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26799351','lexi-content-ref-16182678'])">Ref</a></span>).<b> Note:</b> Pharmacokinetic analysis based on simulation reported that the following age-dependent pediatric doses resulted in exposures similar to adult doses of 30 to 150 mg/day: Children 2 to 6 years: 0.35 to 1.6 mg/kg/day; experiential data are needed to fully assess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31808613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31808613'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;5 years and Adolescents: Oral: Initial: 0.75 to 1 mg/kg/dose or 25 to 50 mg at bedtime; may increase at 2-week intervals in 12.5 to 25 mg increments up to a maximum dose of 200 mg/dose; reported range: 0.5 to 2 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21296553','lexi-content-ref-15843773','lexi-content-ref-Ullrich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21296553','lexi-content-ref-15843773','lexi-content-ref-Ullrich.1'])">Ref</a></span>). When used for palliative care, multiple daily doses may be necessary; in patients &gt;18 years of age, 25 to 50 mg/dose increased gradually to twice or 3 times daily as needed (do not exceed adult dosing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ullrich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ullrich.1'])">Ref</a></span>). <b>Note:</b> Pharmacokinetic analysis based on simulation reported that the following age-dependent pediatric doses resulted in exposures similar to adult doses of 30 to 150 mg/day: Children &gt;6 to 12 years: 0.4 to 1.9 mg/kg/day and Adolescents: 0.4 to 2.1 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31808613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31808613'])">Ref</a></span>); experiential data are needed to fully assess.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a88a9dbf-8161-4267-8b85-a53eda1346a9">Migraine, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prophylaxis:</b> Limited data available: <b>Note:</b> Efficacy results variable; expert recommendations for migraine prevention in children and adolescents do not suggest trazodone as a routine therapeutic option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31413170']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31413170'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: Oral: 1 mg/kg/<b>day</b> in 3 divided doses; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8436497','lexi-content-ref-16674757','lexi-content-ref-15623677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8436497','lexi-content-ref-16674757','lexi-content-ref-15623677'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Due to short half-life of trazodone, avoid abrupt discontinuation to minimize the incidence of withdrawal symptoms, rebound insomnia, or increased nightmares as a result of REM sleep rebound. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the drug; drugs with a shorter half-life may need to be tapered more conservatively. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192983"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific pediatric dosage adjustments; in adult patients, no dosage adjustment is necessary for mild to moderate kidney impairment, and titration should be done with caution. Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6746584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6746584'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51192984"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.</p></div>
<div class="block arsc drugH1Div" id="F54429588"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>mania </b>or <b>hypomania </b>in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic; unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-Patel.2015','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-Patel.2015','lexi-content-ref-19958306'])">Ref</a></span>). May interfere with the balance of neurotransmitter systems when trazodone is added to other antidepressant therapies, like selective serotonin reuptake inhibitors (SSRIs) (eg, sertraline) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset may vary from 4 days to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883733'])">Ref</a></span>). A systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-Patel.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-Patel.2015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8696624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8696624'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-Patel.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-Patel.2015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8696624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8696624'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Trazodone may increase the risk of bleeding, particularly if used concomitantly with antiplatelet and/or anticoagulants. Multiple observational studies with other drugs that interfere with serotonin reuptake (eg, selective serotonin reuptake inhibitors [SSRIs]) have found an association with use and a variety of bleeding complications. Similar to these agents, trazodone may increase the risk of bleeding; however, the risk may be lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Possibly via inhibition of serotonin-mediated platelet activation and subsequent platelet dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>
<i>:</i> Varied; per SSRI-derived literature (ie, trazodone not included), bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of antiplatelets and/or anticoagulants (based on SSRI-derived literature) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiac arrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrhythmias</b>, including <b>prolonged QT interval on ECG</b> (with or without <b>torsades de pointes</b> [TdP]) and <b>ventricular tachycardia,</b> have been reported. Other arrhythmias identified include <b>ventricular premature contractions</b>, ventricular couplets, <b>tachycardia</b> with <b>syncope</b>, <b>sinus bradycardia, first-degree atrioventricular block, </b>and<b> complete atrioventricular block</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2424891','lexi-content-ref-17976767','lexi-content-ref-11603256','lexi-content-ref-23192413','lexi-content-ref-10360146','lexi-content-ref-6496797','lexi-content-ref-2361400','lexi-content-ref-16389666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2424891','lexi-content-ref-17976767','lexi-content-ref-11603256','lexi-content-ref-23192413','lexi-content-ref-10360146','lexi-content-ref-6496797','lexi-content-ref-2361400','lexi-content-ref-16389666'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related (generally, although may also occur at low to moderate doses); QT prolongation may be a result of the concentration-dependent inhibition of human ether-à-go-go (hERG) channel current (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15740727','lexi-content-ref-16389666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15740727','lexi-content-ref-16389666'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Risk factors for drug-induced QT prolongation (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec or lengthening of the QTc by ≥60 msec) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Trazodone may cause significant <b>orthostatic hypotension</b>, which may lead to<b> syncope</b> and subsequent falls and fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-9826316','lexi-content-ref-11126303','lexi-content-ref-1592445','lexi-content-ref-23265229']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-9826316','lexi-content-ref-11126303','lexi-content-ref-1592445','lexi-content-ref-23265229'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Orthostatic hypotension is due to alpha-1 adrenergic receptor blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29552421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29552421'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia/dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medication use that may predispose to hypotension/bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults, especially in those with preexisting heart conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Priapism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Priapism </b>has been reported rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-3966579','lexi-content-ref-6624973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-3966579','lexi-content-ref-6624973'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to the blockade of alpha receptors in the absence of sufficient antimuscarinic activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8696624','lexi-content-ref-29332554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8696624','lexi-content-ref-29332554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually evident within 28 days of beginning treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8019056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8019056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Sickle cell anemia</p>
<p style="text-indent:-2em;margin-left:6em;">• Multiple myeloma</p>
<p style="text-indent:-2em;margin-left:6em;">• Leukemia</p>
<p style="text-indent:-2em;margin-left:6em;">• Anatomical deformation of the penis (eg, angulation, cavernosal fibrosis, Peyronie disease)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serotonin syndrome has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31837902','lexi-content-ref-31030620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31837902','lexi-content-ref-31030620'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism (eg, monoamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, is contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years) in short-term studies. In adults &gt;24 years, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age, a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether the risk extends to longer-term use (&gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Withdrawal syndrome, consisting of both somatic symptoms (eg, dizziness, chills, lightheadedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability), has been reported, primarily following the abrupt discontinuation of selective serotonin reuptake inhibitors (SSRIs) (including case reports with trazodone). Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the serotonergic agent. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as effects on the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2018.1','lexi-content-ref-15906018','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2018.1','lexi-content-ref-15906018','lexi-content-ref-25677972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018.1'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F230252"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (10% to 13%), xerostomia (15% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (20% to 28%), drowsiness (24% to 41%), fatigue (6% to 11%), headache (10% to 20%), nervousness (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (6% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, hypotension (4% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypotension</span>, palpitations, sinus bradycardia, syncope (3% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Syncope table link" class="lexi-table-link" data-table-id="lexi-content-syncope" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-syncope')">table 2</a>)</span><span class="table-link" style="display:none;">Syncope</span>, tachycardia (may include syncope)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension" frame="border" id="lexi-content-hypotension" rules="all">
<caption>
<b>TraZODone: Adverse Reaction: Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Trazodone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trazodone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Inpatients</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Outpatients</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">158</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Syncope" frame="border" id="lexi-content-syncope" rules="all">
<caption>
<b>TraZODone: Adverse Reaction: Syncope</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Trazodone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Trazodone)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Inpatients</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">95</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Outpatients</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">158</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in menstrual flow, increased libido, weight gain (1% to 5%), weight loss (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (7% to 8%), diarrhea (5%), flatulence, gastrointestinal disease (6%), increased appetite, sialorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Early menses, erectile dysfunction, hematuria, retrograde ejaculation, urinary frequency, urinary hesitancy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia, ataxia (2% to 5%), confusion (5%), delusion, disorientation (2%), hallucination, heavy headedness (3%), hypomania, lack of concentration (1% to 3%), malaise (3%), memory impairment, numbness, paresthesia, speech disturbance, tremor (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle twitching, myalgia (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Asthenopia, eye pruritus, eye redness</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, nasal congestion (≤6%), paranasal sinus congestion (≤6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, atrial fibrillation (White 1985), bradycardia (Li 2011), cardiac arrhythmia, cardiac conduction disorder, complete atrioventricular block (Rausch 1984), edema (Barnett 1985), first-degree atrioventricular block (Winkler 2006), heart failure, orthostatic hypotension (Poon 2005; Spivak 1987), prolonged QT interval on ECG (de Meester 2001; Levenson 1999), torsades de pointes (de Meester 2001; Levenson 1999), ventricular ectopy, ventricular tachycardia (Aronson 1986, Vittulo 1990)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, fixed drug eruption (lesions [including bullous]) (Combemale 2020), leukonychia (Longstreth 1985), psoriasis (Barth 1986), skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hirsutism, SIADH</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Sheikh 1983), esophageal achalasia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast engorgement, breast hypertrophy, female sexual disorder (Battaglia 2009; Purcell 1995), lactation, priapism (Raskin 1985; Scher 1983), urinary incontinence, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, leukocytosis, methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Fernandes 2000; Rettman 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, anxiety, aphasia, cerebrovascular accident, delirium (Lennkh 1998), extrapyramidal reaction (Sotto 2015), insomnia, mania (Hu 2017), paranoid ideation, parkinsonism (Sharma 2022), psychosis (Mizoguchi 2005), restless leg syndrome (Yilbaş 2022), seizure (Vanpee 1999), serotonin syndrome (Duignan 2019; Hudd 2010), stupor, tardive dyskinesia (Lin 2008), vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea</p></div>
<div class="block coi drugH1Div" id="F230267"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to trazodone or any component of the formulation; use of monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either trazodone or the MAOI); initiation of trazodone in a patient receiving IV methylene blue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Although trazodone is contraindicated per the manufacturer labeling when used in combination with linezolid, new evidence suggests that the combination is unlikely to cause serotonin syndrome (0.06% to 3% risk), and therefore these agents can be administered concomitantly when necessary. Monitor patients on this combination; average duration of serotonin toxicity is ~4 days; however, risks may be greater with longer durations of concurrent therapy. Educate patients on the signs and symptoms of serotonin syndrome (Bai 2022; Butterfield 2012; Karkow 2017; Kufel 2023; Narita 2007; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F230249"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Falls: May cause falls and major osteoporotic fractures (eg, hip, pelvis, humerus, forearm) when used in elderly patients. The fall rate was found to be similar to the rates associated with antipsychotics and benzodiazepines (Bronskill 2018; Watt 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May cause mild pupillary dilation, which can lead to an episode of narrow-angle glaucoma in susceptible individuals. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: Not recommended for use in a patient during the acute recovery phase of MI due to exacerbation of arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; has not been studied in hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications that may lower seizure threshold (Hill 2015).</p></div>
<div class="block foc drugH1Div" id="F230259"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 150 mg, 300 mg</p></div>
<div class="block geq drugH1Div" id="F230245"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F230269"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (traZODone HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.15 - $1.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.21 - $1.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.52 - $2.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $5.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868483"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 150 mg</p></div>
<div class="block adm drugH1Div" id="F230264"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer shortly after a meal or light snack; swallow whole or as a half tablet by breaking along the score line.</p></div>
<div class="block admp drugH1Div" id="F52613961"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer after meals or a snack to decrease lightheadedness, sedation, and postural hypotension; swallow whole or as a half tablet by breaking along the score line.</p></div>
<div class="block meg drugH1Div" id="F9837787"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Desyrel: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F018207s032lbl.pdf%23page%3D13&amp;token=OJNu0vrkQJszxJeDYG95GcwUKlZcMDBM7QJfvJBYXsEFUEEI1xW8lJrmP93JcvbSF0YhL5hcI0MQZxjmVFNjxWXM3o8jp2ooYPeBS0P3y9G43X56MXg%2B7spVUJgOyek%2F&amp;TOPIC_ID=10013" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf#page=13</a></p>
<p style="text-indent:-2em;margin-left:4em;">Antidepressant medications: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FInformationbyDrugClass%2Fucm100211.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F%2BtzXKjYwuZYZylkP%2BkRnn%2BdoVL8tsWmc2MIZh%2Fg1QzjAAGI4EzKpddG0l%2Fj8K0NuhbXvXOgWPXisGp8KlvcP9h&amp;TOPIC_ID=10013" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf</a></p></div>
<div class="block use drugH1Div" id="F230263"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Major depressive disorder (unipolar): </b>Treatment of unipolar major depressive disorder</p></div>
<div class="block off-label drugH1Div" id="F25744923"><span class="drugH1">Use: Off-Label: Adult</span><p>Aggressive or agitated behavior associated with dementia; Insomnia, sleep onset and sleep maintenance</p></div>
<div class="block mst drugH1Div" id="F230325"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Desyrel may be confused with deferoxamine, Demerol, Delsym, Seroquel, Zestril</p>
<p style="text-indent:-2em;margin-left:4em;">TraZODone may be confused with traMADol, ziprasidone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F230311"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F230254"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of TraZODone. Specifically, effects on sleepiness, dizziness, and manual dexterity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Serotonin Reuptake Inhibitor/Antagonists may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of CarBAMazepine. Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers, such as carbamazepine. In addition, monitor for increased carbamazepine concentrations and effects during coadministration with trazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of TraZODone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of TraZODone. Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of TraZODone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of TraZODone. Management: Consider the use of a lower trazodone dose and monitor for increased trazodone effects (eg, sedation, QTc prolongation) if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Fosphenytoin. Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers, such as fosphenytoin. In addition, monitor for increased phenytoin concentrations and effects during coadministration with trazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: TraZODone may enhance the CNS depressant effect of Mirtazapine. TraZODone may enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and CNS depression when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: TraZODone may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of TraZODone.  Management: Consider the use of a lower trazodone dose and monitor for increased trazodone effects such as sedation, QTc prolongation, and signs and symptoms of serotonin syndrome/serotonin toxicity when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin. Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers, such as phenytoin. In addition, monitor for increased phenytoin concentrations and effects during coadministration with trazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May enhance the QTc-prolonging effect of TraZODone. Saquinavir may increase the serum concentration of TraZODone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): Serotonergic Non-Opioid CNS Depressants may enhance the CNS depressant effect of Serotonergic Opioids (High Risk). Serotonergic Non-Opioid CNS Depressants may enhance the serotonergic effect of Serotonergic Opioids (High Risk). This could result in serotonin syndrome.  Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity and CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: TraZODone may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the CNS depressant effect of Serotonergic Non-Opioid CNS Depressants. Tricyclic Antidepressants may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and CNS depression when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: TraZODone may diminish the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F230277"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Time to peak serum levels may be increased if taken with food. Management: Administer after a meal or light snack.</p></div>
<div class="block pri drugH1Div" id="F5722230"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Trazodone and the active metabolite 1-m-chlorophenylpiperazine cross the placenta and can be detected in cord blood at delivery (Saito 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Based on available data, an increased risk of adverse pregnancy outcomes has not been observed following use of trazodone during pregnancy (Anderson 2020; Einarson 2003; Einarson 2009). Long-term effects on neurodevelopment are not known (Korade 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006). However, if treatment for major depressive disorder is initiated for the <b>first time</b> during pregnancy, trazodone is not one of the preferred medications (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Trazodone has also been evaluated for the treatment of insomnia. A randomized, placebo-controlled study in pregnant patients found trazodone (n = 18) to improve total sleep duration and sleep efficacy after 6 weeks of treatment compared to placebo (n = 17). In addition, the risk of postpartum depression was decreased. Treatment began during the third trimester and patients had no underlying sleep or mood disorders prior to pregnancy. Daytime sleepiness was a common adverse event (Khazaie 2013). In nonpregnant patients, trazodone is not the preferred treatment when cognitive behavioral therapies are not adequate because harm outweighs benefit (AASM [Sateia 2017]). Cognitive behavioral therapy is also effective in pregnant patients and is the currently preferred treatment (Bacaro 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry by calling 1-844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>
<div class="block brc drugH1Div" id="F5634584"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Trazodone and the active metabolite 1-m-chlorophenylpiperazine (mCPP) are present in breast milk (Saito 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of trazodone in breast milk is available from a study that administered a single dose of trazodone 50 mg to 6 otherwise healthy breastfeeding women, 3 to 8 months postpartum. Breast milk was sampled over 24 hours. The presence of trazodone metabolites was not evaluated. Trazodone concentrations in breast milk peaked about 2 hours following administration, approximately the same time as in the plasma (Verbeeck 1986). Using data from this study, the relative infant dose (RID) of trazodone was calculated to be 2% of the weight-adjusted maternal dose, based on the highest breast milk concentration (100 ng/mL), providing an estimated daily infant dose via breast milk of 0.015 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of trazodone and mCPP in breast milk is available from a patient following use of trazodone 50 mg daily during pregnancy and postpartum. Breast milk was sampled after 5 days of therapy. The highest concentrations of trazodone (50.2 ng/mL) and mCPP (3.2 ng/mL) in breast milk were in the sample obtained 7.2 hours after a maternal dose. Using the highest breast milk concentration of trazodone, authors of this study calculated the RID to be 0.8% of the weight-adjusted maternal dose, providing an estimated daily infant dose via breast milk of 0.008 mg/kg/day. The infant was partially breastfed with &gt;50% of nutrition from breast milk. Trazodone and mCPP were detected in infant serum 14.2 hours after birth (156.6 ng/mL and 9.8 ng/mL, respectively) and decreased significantly by postpartum day 5 (1.3 ng/mL and &lt;0.2 ng/mL, respectively). This infant required oxygen due to a persistent respiratory disturbance for the first 4 days after birth (mother also taking etizolam); however, no drug-related adverse events were observed in the infant up to 6 months of age (Saito 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional information related to the use of trazodone in breastfeeding women is limited (Misri 1991; Misri 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Infants exposed to antidepressants via breast milk should be monitored for changes in sleep, feeding patterns, and behavior as well as growth and development (Sachs 2013; WFSBP [Bauer 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Psychotherapy or other nonmedication therapies are recommended for the initial treatment of mild depression in breastfeeding patients; antidepressant medication is recommended when psychotherapy is not an option or symptoms are moderate to severe. If a specific medication was used effectively during pregnancy, it can be continued while breastfeeding if no contraindications exist (ABM [Sriraman 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">When first initiating an antidepressant in a breastfeeding patient, agents other than trazodone are preferred (ABM [Sriraman 2015]; CANMAT [MacQueen 2016]; Larsen 2015).</p></div>
<div class="block mop drugH1Div" id="F4794638"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline liver function prior to and periodically during therapy; closely monitor patients for depression, clinical worsening, suicidality, psychosis, or unusual changes in behavior (eg. anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); signs/symptoms of hypotension or orthostasis.</p></div>
<div class="block pha drugH1Div" id="F230248"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits reuptake of serotonin, causes adrenoreceptor subsensitivity, acts as a 5HT<sub>2a</sub> receptor antagonist and induces significant changes in 5-HT presynaptic receptor adrenoreceptors. Trazodone also significantly blocks histamine (H<sub>1</sub>) and alpha1-adrenergic receptors.</p></div>
<div class="block phk drugH1Div" id="F230266"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed. Food increases absorption, decreases peak concentration and delays time to peak concentration.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 89% to 95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 (extensive) to an active metabolite (mCPP).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 100% (Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5 to 9 hours, prolonged in obese patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 30 to 100 minutes; delayed with food (up to 2.5 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (74%, &lt;1% excreted unchanged); secondarily feces (~21%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038849"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Taxagon ad</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Doctrazodone | Nestrolan | Trazodone eg | Trazodone sandoz | Trazolan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Trittico | Trittico xr</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Andhora | Cloridrato de trazodona | Donaren | Inseris xr | Loredon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Trazodon sandoz | Trittico</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Codipzona | Codipzona sr | Diapresan | Trant | Trittico | Tronsalan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Mei su yu | Mesyrel | Shu xu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Trazodona | Trazodona clorhidrato | Trazodona hcl | Trazodona lakor | Trazodone | Trittico | Trittico ac</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Trittico ac | Trittico prolong</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Thombran | Trazodon glenmark | Trazodon hexal | Trazodon Neuraxpharm</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Trarett</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Deprax | Suxatrin | Trazodona accord | Trazodona normon | Trazodona sandoz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Tramensan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Molipaxin | Trazodone | Trazodone Actavis | Trazodone kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo trazodone | Pms Trazodone | Trazopress | Trittico</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Depsan | Trittico ac</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Trazone</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Molipaxin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Depyrel | Trazodil | Trittico</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Depryl | Trazalon | Trazaril | Traze | Trazomet | Trazonil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Desyrel | Reslin | Undepre</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Myungin trazodone hcl | Serazon | Trittico | Trittico er</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trazodone | Trazodone eg | Trazolan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Trazodon Neuraxpharm | Trazodona Generis | Trittico ac</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Frizotex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Trazodon hydrochloride accord | Trazodone HCL | Trazolan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apo trazodone | Trazodon | Trazodon Neuraxpharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Trazodone | Trazodone accord</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Depresil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dazod | Deprel | Trazolam | Zazadone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Thombran | Trazodone glenmark | Trittico</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Desyrel | Oleptro | Trazodone HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Trazodona | Trazodona Farmoz | Trazodona Generis | Trazodona Mepha | Trazodona wynn | Trazone | Trazone ac | Trazone od | Triticum | Triticum od</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Trazopax | Trittico</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Desyrel</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Trittico ac | Trittico ep</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Desyrel | Pms Trazodone | Trazolan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Trittico</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Devidon | Trittico</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trazodone glenmark | Trittico</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Desirel | Dezodone | Trazadol | Trazo | Trazodel | Trazodone Pharmasant | Zorel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Desirel</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cirzodone | Fishdon | Mesyrel | Reslin | Torlex | Trazo | Trazodone | Trazone | Trittico</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Trazodone</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Taxagon AC</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Trazaril | Trittico</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Trazopax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2006">
<a name="APA.2006"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with substance use disorders. 2nd ed. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf. Published August 2006. Accessed August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565‐1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2424891">
<a name="2424891"></a>Aronson MD, Hafez H. A case of trazodone-induced ventricular tachycardia. <i>J Clin Psychiatry</i>. 1986;47(7):388‐389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/2424891/pubmed" id="2424891" target="_blank">2424891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3802006">
<a name="3802006"></a>Asayesh K. Combination of trazodone and phenothiazines: a possible additive hypotensive effect. <i>Can J Psychiatry</i>. 1986;31(9):857‐858. doi:10.1177/070674378603100913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3802006/pubmed" id="3802006" target="_blank">3802006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31801099">
<a name="31801099"></a>Bacaro V, Benz F, Pappaccogli A, et al. Interventions for sleep problems during pregnancy: a systematic review. <i>Sleep Med Rev</i>. 2020;50:101234. doi:10.1016/j.smrv.2019.101234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31801099/pubmed" id="31801099" target="_blank">31801099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36534400">
<a name="36534400"></a>Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. <i>JAMA Netw Open</i>. 2022;5(12):e2247426. doi:10.1001/jamanetworkopen.2022.47426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/36534400/pubmed" id="36534400" target="_blank">36534400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129‐135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-Induced Serotonin Syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49‐54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998206">
<a name="3998206"></a>Barrnett J, Frances A, Kocsis J, Brown R, Mann JJ. Peripheral edema associated with trazodone: a report of ten cases. <i>J Clin Psychopharmacol</i>. 1985;5(3):161‐164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3998206/pubmed" id="3998206" target="_blank">3998206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3790438">
<a name="3790438"></a>Barth JH, Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. <i>Br J Dermatol</i>. 1986;115(5):629‐630. doi:10.1111/j.1365-2133.1986.tb05776.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3790438/pubmed" id="3790438" target="_blank">3790438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19674253">
<a name="19674253"></a>Battaglia C, Venturoli S. Persistent genital arousal disorder and trazodone. Morphometric and vascular modifications of the clitoris. A case report. <i>J Sex Med</i>. 2009;6(10):2896‐2900. doi:10.1111/j.1743-6109.2009.01418.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/19674253/pubmed" id="19674253" target="_blank">19674253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8436497">
<a name="8436497"></a>Battistella PA, Ruffilli R, Cernetti R, et al. A placebo-controlled crossover trial using trazodone in pediatric migraine. <i>Headache</i>. 1993;33(1):36-39. doi:10.1111/j.1526-4610.1993.hed3301036.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/8436497/pubmed" id="8436497" target="_blank">8436497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186‐194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26799351">
<a name="26799351"></a>Blackmer AB, Feinstein JA. Management of sleep disorders in children with neurodevelopmental disorders: a review. <i>Pharmacotherapy</i>. 2016;36(1):84-98. doi:10.1002/phar.1686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/26799351/pubmed" id="26799351" target="_blank">26799351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888714">
<a name="28888714"></a>Bobo WV. The diagnosis and management of bipolar I and II disorders: Clinical practice update. <i>Mayo Clin Proc</i>. 2017;92(10):1532‐1551. doi:10.1016/j.mayocp.2017.06.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/28888714/pubmed" id="28888714" target="_blank">28888714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20689123">
<a name="20689123"></a>Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. <i>Am J Health Syst Pharm. </i>2010;67(16):1344-1350. doi:10.2146/ajhp090477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/20689123/pubmed" id="20689123" target="_blank">20689123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247773">
<a name="30247773"></a>Bronskill SE, Campitelli MA, Iaboni A, et al. Low-dose trazodone, benzodiazepines, and fall-related injuries in nursing homes: a matched-cohort study. <i>J Am Geriatr Soc</i>. 2018;66(10):1963-1971. doi:10.1111/jgs.15519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/30247773/pubmed" id="30247773" target="_blank">30247773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31638842">
<a name="31638842"></a>Bruni O, Angriman M, Melegari MG, Ferri R. Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders. <i>Expert Opin Pharmacother</i>. 2019;20(18):2257-2271. doi:10.1080/14656566.2019.1674283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31638842/pubmed" id="31638842" target="_blank">31638842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139199">
<a name="22139199"></a>Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. <i>J Antimicrob Chemother</i>. 2012;67(2):494-502. doi:10.1093/jac/dkr467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/22139199/pubmed" id="22139199" target="_blank">22139199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3339747">
<a name="3339747"></a>Carson CC 3rd, Mino RD. Priapism associated with trazodone therapy. <i>J Urol</i>. 1988;139(2):369‐370. doi:10.1016/s0022-5347(17)42419-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3339747/pubmed" id="3339747" target="_blank">3339747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270‐288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-743386">
<a name="743386"></a>Catanese B, Dionisio A, Barillari G, De Martino C. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function. <i>Boll Chim Farm</i>. 1978;117(7):424-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/743386/pubmed" id="743386" target="_blank">743386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17976767">
<a name="17976767"></a>Chung KJ, Wang YC, Liu BM, Supernaw RB. Management of ventricular dysrhythmia secondary to trazodone overdose. <i>J Emerg Med</i>. 2008;35(2):171‐174. doi:10.1016/j.jemermed.2007.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/17976767/pubmed" id="17976767" target="_blank">17976767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31742734">
<a name="31742734"></a>Combemale L, Ben Saïd B, Dupire G. Generalized bullous fixed drug eruption: trazodone as a new culprit. <i>Contact Dermatitis</i>. 2020;82(3):192-193. doi:10.1111/cod.13436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31742734/pubmed" id="31742734" target="_blank">31742734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16674757">
<a name="16674757"></a>Damen L, Bruijn J, Verhagen AP, Berger MY, Passchier J, Koes BW. Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials. <i>Cephalalgia</i>. 2006;26(5):497-505. doi:10.1111/j.1468-2982.2005.01047.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16674757/pubmed" id="16674757" target="_blank">16674757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11603256">
<a name="11603256"></a>de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. <i>Acta Clin Belg</i>. 2001;56(4):258‐261. doi:10.1179/acb.2001.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/11603256/pubmed" id="11603256" target="_blank">11603256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Desyrel.2018.10">
<a name="Desyrel.2018.10"></a>Desyrel (trazodone) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6746584">
<a name="6746584"></a>Doweiko J, Fogel BS, Goldberg RJ. Trazodone and hemodialysis. <i>J Clin Psychiatry</i>. 1984;45(8):361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/6746584/pubmed" id="6746584" target="_blank">6746584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31837902">
<a name="31837902"></a>Duignan KM, Quinn AM, Matson AM. Serotonin syndrome from sertraline monotherapy: A case report [published online ahead of print, 2019 Nov 16]. <i>Am J Emerg Med</i>. 2019;158487. doi:10.1016/j.ajem.2019.158487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31837902/pubmed" id="31837902" target="_blank">31837902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12655908">
<a name="12655908"></a>Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. <i>Can J Psychiatry</i>. 2003;48(2):106-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/12655908/pubmed" id="12655908" target="_blank">12655908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19321030">
<a name="19321030"></a>Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. <i>Can J Psychiatry.</i> 2009;54(4):242-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/19321030/pubmed" id="19321030" target="_blank">19321030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23192413">
<a name="23192413"></a>Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. <i>CNS Drugs</i>. 2012;26(12):1033‐1049. doi:10.1007/s40263-012-0010-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23192413/pubmed" id="23192413" target="_blank">23192413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72‐81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10685763">
<a name="10685763"></a>Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. <i>Am J Gastroenterol</i>. 2000;95(2):532‐535. doi:10.1111/j.1572-0241.2000.t01-1-01780.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/10685763/pubmed" id="10685763" target="_blank">10685763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18616688">
<a name="18616688"></a>Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. <i>Alcohol Clin Exp Res</i>. 2008;32(9):1652-1660. doi:10.1111/j.1530-0277.2008.00742.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18616688/pubmed" id="18616688" target="_blank">18616688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343‐2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28554948">
<a name="28554948"></a>Gabriel M, Sharma V. Antidepressant discontinuation syndrome. <i>CMAJ</i>. 2017;189(21):E747. doi:10.1503/cmaj.160991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/28554948/pubmed" id="28554948" target="_blank">28554948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47‐59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332‐339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8019056">
<a name="8019056"></a>Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. <i>Drugs Aging</i>. 1994;4(4):331‐355. doi:10.2165/00002512-199404040-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/8019056/pubmed" id="8019056" target="_blank">8019056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26678837">
<a name="26678837"></a>Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years; cohort study using a primary care database. <i>BMC Psychiatry </i>2015;15:315. doi:10.1186/s12888-015-0701-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/26678837/pubmed" id="26678837" target="_blank">26678837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018.1">
<a name="Hirsch.2018.1"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018.3">
<a name="Hirsch.2018.3"></a>Hirsch M, Birnbaum RJ. Serotonin modulators: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018.2">
<a name="Hirsch.2018.2"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21296553">
<a name="21296553"></a>Hollway JA, Aman MG. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature. <i>Res Dev Disabil</i>. 2011;32(3):939-962. doi:10.1016/j.ridd.2010.12.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/21296553/pubmed" id="21296553" target="_blank">21296553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883733">
<a name="28883733"></a>Hu J, Lai J, Zheng H, Hu S, Xu Y. Fan the flame: trazodone-induced mania in a unipolar depressed patient with stable sertraline treatment. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2251‐2254. doi:10.2147/NDT.S143965<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/28883733/pubmed" id="28883733" target="_blank">28883733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31030620">
<a name="31030620"></a>Hudd TR, Blake CS, Rimola-Dejesus Y, Nguyen TT, Zaiken K. A case report of serotonin syndrome in a patient on selective serotonin reuptake inhibitor (SSRI) monotherapy. <i>J Pharm Pract</i>. 2020;33(2):206‐212. doi:10.1177/0897190019841742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31030620/pubmed" id="31030620" target="_blank">31030620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288069">
<a name="21288069"></a>Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. <i>World J Biol Psychiatry</i>. 2011;12(1):2-32. doi:10.3109/15622975.2010.538083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/21288069/pubmed" id="21288069" target="_blank">21288069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29552421">
<a name="29552421"></a>Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. <i>Innov Clin Neurosci</i>. 2017;14(7-8):24‐34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/29552421/pubmed" id="29552421" target="_blank">29552421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176‐1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28796019">
<a name="28796019"></a>Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. <i>J Clin Psychopharmacol</i>. 2017;37(5):518-523. doi:10.1097/JCP.0000000000000751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/28796019/pubmed" id="28796019" target="_blank">28796019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790‐792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23993464">
<a name="23993464"></a>Khazaie H, Ghadami MR, Knight DC, Emamian F, Tahmasian M. Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. <i>Psychiatry Res</i>. 2013;210(3):901-905. doi:10.1016/j.psychres.2013.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23993464/pubmed" id="23993464" target="_blank">23993464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18004149">
<a name="18004149"></a>Klier CM, Mossaheb N, Saria A, et al. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. <i>J Clin Psychopharmacol.</i> 2007;27(6):720-722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18004149/pubmed" id="18004149" target="_blank">18004149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33526772">
<a name="33526772"></a>Korade Z, Allen LB, Anderson A, et al. Trazodone effects on developing brain. <i>Transl Psychiatry</i>. 2021;11(1):85. doi:10.1038/s41398-021-01217-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/33526772/pubmed" id="33526772" target="_blank">33526772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15843773">
<a name="15843773"></a>Kratochvil CJ, Lake M, Pliszka SR, Walkup JT. Pharmacological management of treatment-induced insomnia in ADHD. <i>J Am Acad Child Adolesc Psychiatry. </i>2005;44(5):499-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15843773/pubmed" id="15843773" target="_blank">15843773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37160238">
<a name="37160238"></a>Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents. <i>Int J Antimicrob Agents</i>. 2023;62(1):106843. doi:10.1016/j.ijantimicag.2023.106843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/37160238/pubmed" id="37160238" target="_blank">37160238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12920414">
<a name="12920414"></a>Le Bon O, Murphy JR, Staner L, et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. <i>J Clin Psychopharmacol</i>. 2003;23(4):377-383. doi:10.1097/01.jcp.0000085411.08426.d3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/12920414/pubmed" id="12920414" target="_blank">12920414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15178953">
<a name="15178953"></a>Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. <i>Dement Geriatr Cogn Disord</i>. 2004;17(4):355-359. doi:10.1159/000077171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15178953/pubmed" id="15178953" target="_blank">15178953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9817628">
<a name="9817628"></a>Lennkh C, Fischer P, Küfferle B, Kasper S. Occurrence of trazodone-induced delirium. <i>Int Clin Psychopharmacol</i>. 1998;13(5):225‐228. doi:10.1097/00004850-199809000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/9817628/pubmed" id="9817628" target="_blank">9817628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786‐1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10360146">
<a name="10360146"></a>Levenson JL. Prolonged QT interval after trazodone overdose. <i>Am J Psychiatry</i>. 1999;156(6):969‐970. doi:10.1176/ajp.156.6.969a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/10360146/pubmed" id="10360146" target="_blank">10360146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15623677">
<a name="15623677"></a>Lewis D, Ashwal S, Hershey A, et al. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. <i>Neurology.</i> 2004;63(12):2215-2224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15623677/pubmed" id="15623677" target="_blank">15623677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23050923">
<a name="23050923"></a>Li TC, Chiu HW, Ho KJ, Tzeng DS. Bradycardia following a single low dose of trazodone. <i>Asian J Psychiatr</i>. 2011;4(1):77‐79. doi:10.1016/j.ajp.2010.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23050923/pubmed" id="23050923" target="_blank">23050923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18562067">
<a name="18562067"></a>Lin CC, Lin PY, Lee Y, Chang YY, Chen CH. Tardive dystonia and tardive sensory syndrome related to trazodone: a case report. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(6):1609‐1610. doi:10.1016/j.pnpbp.2008.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18562067/pubmed" id="18562067" target="_blank">18562067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4031146">
<a name="4031146"></a>Longstreth GF, Hershman J. Trazodone-induced hepatotoxicity and leukonychia. <i>J Am Acad Dermatol</i>. 1985;13(1):149‐150. doi:10.1016/s0190-9622(85)80328-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/4031146/pubmed" id="4031146" target="_blank">4031146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773‐780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9826316">
<a name="9826316"></a>Masaki KH, Schatz IJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. <i>Circulation</i>. 1998;98(21):2290‐2295. doi:10.1161/01.cir.98.21.2290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/9826316/pubmed" id="9826316" target="_blank">9826316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201‐209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24659320">
<a name="24659320"></a>McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. <i>Cochrane Database Syst Rev</i>. 2014;(3):CD009178. doi:10.1002/14651858.CD009178.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/24659320/pubmed" id="24659320" target="_blank">24659320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15816789">
<a name="15816789"></a>Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. <i>J Clin Psych</i>. 2005;66(4):469-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15816789/pubmed" id="15816789" target="_blank">15816789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16974194">
<a name="16974194"></a>Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. <i>J Clin Psychopharmacol</i>. 2006;26(5):508-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16974194/pubmed" id="16974194" target="_blank">16974194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1894455">
<a name="1894455"></a>Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. <i>Int J Psychiatry Med</i>. 1991;21(2):157-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/1894455/pubmed" id="1894455" target="_blank">1894455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15939985">
<a name="15939985"></a>Mizoguchi Y, Monji A. Low-dose-trazodone-induced disorganized type psychosis. <i>J Neuropsychiatry Clin Neurosci</i>. 2005;17(2):253‐254. doi:10.1176/jnp.17.2.253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15939985/pubmed" id="15939985" target="_blank">15939985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult toxicology in critical care: Part II: Specific poisonings. <i>Chest.</i> 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17655517">
<a name="17655517"></a>Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. <i>Pharmacotherapy</i>. 2007;27(8):1189-1197. doi:10.1592/phco.27.8.1189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/17655517/pubmed" id="17655517" target="_blank">17655517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31808613">
<a name="31808613"></a>Oggianu L, Ke AB, Chetty M, et al. Estimation of an appropriate dose of trazodone for pediatric insomnia and the potential for a trazodone-atomoxetine interaction. <i>CPT Pharmacometrics Syst Pharmacol</i>. 2020;9(2):77-86. doi:10.1002/psp4.12480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31808613/pubmed" id="31808613" target="_blank">31808613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults.<i> J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11126303">
<a name="11126303"></a>Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. <i>Am J Med</i>. 2000;108(2):106‐111. doi:10.1016/s0002-9343(99)00425-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/11126303/pubmed" id="11126303" target="_blank">11126303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413170">
<a name="31413170"></a>Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. <i>Neurology</i>. 2019;93(11):500-509. doi:10.1212/WNL.0000000000008105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/31413170/pubmed" id="31413170" target="_blank">31413170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20621556">
<a name="20621556"></a>Owens JA, Rosen CL, Mindell JA, et al. Use of pharmacotherapy for insomnia in child psychiatry practice: A national survey. <i>Sleep Med.</i> 2010;11(7):692-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/20621556/pubmed" id="20621556" target="_blank">20621556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8696624">
<a name="8696624"></a>Patel AG, Mukherji K, Lee A. Priapism associated with psychotropic drugs. <i>Br J Hosp Med</i>. 1996;55(6):315‐319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/8696624/pubmed" id="8696624" target="_blank">8696624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patel.2015">
<a name="Patel.2015"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open. </i>2015;5:e008341. doi:10.1136/bmjopen-2015-008341</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15811171">
<a name="15811171"></a>Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. <i>J Clin Pharm Ther</i>. 2005;30(2):173‐178. doi:10.1111/j.1365-2710.2005.00629.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15811171/pubmed" id="15811171" target="_blank">15811171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16182678">
<a name="16182678"></a>Pranzatelli MR, Tate ED, Dukart WS, Flint MJ, Hoffman MT, Oksa AE. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. <i>J Pediatr</i>. 2005;147(3):372-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16182678/pubmed" id="16182678" target="_blank">16182678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Press.2019">
<a name="Press.2019"></a>Press D. Management of neuropsychiatric symptoms of dementia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com.</a> Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7593719">
<a name="7593719"></a>Purcell P, Ghurye R. Trazodone and spontaneous orgasms in an elderly postmenopausal woman: a case report. <i>J Clin Psychopharmacol</i>. 1995;15(4):293‐295. doi:10.1097/00004714-199508000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/7593719/pubmed" id="7593719" target="_blank">7593719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27136449">
<a name="27136449"></a>Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med</i>. 2016;165(2):125-133. doi:10.7326/M15-2175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/27136449/pubmed" id="27136449" target="_blank">27136449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18340692">
<a name="18340692"></a>Rabins PV, Blacker D, Rovner BW, et al; APA Work Group on Alzheimer's Disease and other Dementias; Steering Committee on Practice Guidelines. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. <i>Am J Psychiatry</i>. 2007;164(12)(suppl):5-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18340692/pubmed" id="18340692" target="_blank">18340692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3966579">
<a name="3966579"></a>Raskin DE. Trazodone and priapism. <i>Am J Psychiatry</i>. 1985;142(1):142‐143. doi:10.1176/ajp.142.1.142b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3966579/pubmed" id="3966579" target="_blank">3966579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6496797">
<a name="6496797"></a>Rausch JL, Pavlinac DM, Newman PE. Complete heart block following a single dose of trazodone. <i>Am J Psychiatry</i>. 1984;141(11):1472‐1473. doi:10.1176/ajp.141.11.1472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/6496797/pubmed" id="6496797" target="_blank">6496797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227‐234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11793619">
<a name="11793619"></a>Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. <i>Ann Pharmacother</i>. 2001;35(12):1559‐1561. doi:10.1345/aph.10406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/11793619/pubmed" id="11793619" target="_blank">11793619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013‐1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1592445">
<a name="1592445"></a>Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. <i>Hypertension</i>. 1992;19(6, pt 1):508‐519. doi:10.1161/01.hyp.19.6.508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/1592445/pubmed" id="1592445" target="_blank">1592445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34348038">
<a name="34348038"></a>Saito J, Ishii M, Mito A, et al. Trazodone levels in maternal serum, cord blood, breast milk, and neonatal serum. <i>Breastfeed Med</i>. Published online August 3, 2021. doi:10.1089/bfm.2021.0191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/34348038/pubmed" id="34348038" target="_blank">34348038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998379">
<a name="27998379"></a>Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. <i>J Clin Sleep Med</i>. 2017;13(2):307-349. doi:10.5664/jcsm.6470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/27998379/pubmed" id="27998379" target="_blank">27998379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6624973">
<a name="6624973"></a>Scher M, Krieger JN, Juergens S. Trazodone and priapism. <i>Am J Psychiatry</i>. 1983;140(10):1362‐1363. doi:10.1176/ajp.140.10.1362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/6624973/pubmed" id="6624973" target="_blank">6624973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29332554">
<a name="29332554"></a>Settimo L, Taylor D. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. <i>J Psychopharmacol</i>. 2018;32(1):96‐104. doi:10.1177/0269881117742101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/29332554/pubmed" id="29332554" target="_blank">29332554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35102822">
<a name="35102822"></a>Sharma KD, Colangelo T, Mills A. Trazodone-induced parkinsonism: a case report. <i>Int J Clin Pharmacol Ther</i>. 2022;60(4):184-187. doi:10.5414/CP204068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/35102822/pubmed" id="35102822" target="_blank">35102822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6625402">
<a name="6625402"></a>Sheikh KH, Nies AS. Trazodone and intrahepatic cholestasis. <i>Ann Intern Med</i>. 1983;99(4):572. doi:10.7326/0003-4819-99-4-572_1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/6625402/pubmed" id="6625402" target="_blank">6625402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26174731">
<a name="26174731"></a>Sotto Mayor J, Pacheco AP, Esperança S, Oliveira e Silva A. Trazodone in the elderly: risk of extrapyramidal acute events. <i>BMJ Case Rep</i>. 2015;2015:bcr2015210726. doi:10.1136/bcr-2015-210726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/26174731/pubmed" id="26174731" target="_blank">26174731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3674239">
<a name="3674239"></a>Spivak B, Radvan M, Shine M. Postural hypotension with syncope possibly precipitated by trazodone. <i>Am J Psychiatry</i>. 1987;144(11):1512‐1513. doi:10.1176/ajp.144.11.1512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3674239/pubmed" id="3674239" target="_blank">3674239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9169246">
<a name="9169246"></a>Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. <i>Am J Geriatr Psychiatry</i>. 1997;5(1):60-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/9169246/pubmed" id="9169246" target="_blank">9169246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587‐596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22777411">
<a name="22777411"></a>Tanimukai H, Murai T, Okazaki N, et al. An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. <i>Am J Hosp Palliat Care</i>. 2013;30(4):359-362. doi:10.1177/1049909112452334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/22777411/pubmed" id="22777411" target="_blank">22777411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15740727">
<a name="15740727"></a>Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. <i>Eur J Pharmacol</i>. 2005;510(1-2):75‐85. doi:10.1016/j.ejphar.2005.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15740727/pubmed" id="15740727" target="_blank">15740727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16779744">
<a name="16779744"></a>Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. <i>Clin Infect Dis</i>. 2006;43(2):180-187. doi:10.1086/504809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16779744/pubmed" id="16779744" target="_blank">16779744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479‐487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381‐390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404‐414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trazodone.2009.02">
<a name="Trazodone.2009.02"></a>Trazodone hydrochloride immediate release [prescribing information]. Toronto, Ontario: Apotex Inc; February 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trazodone.2018.11">
<a name="Trazodone.2018.11"></a>Trazodone hydrochloride tablet [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ullrich.1">
<a name="Ullrich.1"></a>Ullrich C, Duncan J, Joselow M, Wolfe J. Pediatric palliative care. In: Kliegman RM, St Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2019: 818.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.2019">
<a name="VADoD.2019"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea. <a href="https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf</a>. Published October 2019. Accessed April 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23265229">
<a name="23265229"></a>van Hateren KJ, Kleefstra N, Blanker MH, et al. Orthostatic hypotension, diabetes, and falling in older patients: a cross-sectional study. <i>Br J Gen Pract</i>. 2012;62(603):e696‐e702. doi:10.3399/bjgp12X656838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/23265229/pubmed" id="23265229" target="_blank">23265229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10452450">
<a name="10452450"></a>Vanpee D, Laloyaux P, Gillet JB. Seizure and hyponatraemia after overdose of trazadone. <i>Am J Emerg Med</i>. 1999;17(4):430‐431. doi:10.1016/s0735-6757(99)90104-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/10452450/pubmed" id="10452450" target="_blank">10452450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3768252">
<a name="3768252"></a>Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. <i>Br J Clin Pharmacol.</i> 1986;22(3):367-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3768252/pubmed" id="3768252" target="_blank">3768252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2361400">
<a name="2361400"></a>Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. <i>Chest</i>. 1990;98(1):247‐248. doi:10.1378/chest.98.1.247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/2361400/pubmed" id="2361400" target="_blank">2361400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Walsh.1">
<a name="Walsh.1"></a>Walsh J, Erman M, Erwin C, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. <i>Hum Psychopharmacol.</i> 1998;13(3):191-198.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3584080">
<a name="3584080"></a>Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. <i>J Clin Psychiatry</i>. 1987;48(6):244‐245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3584080/pubmed" id="3584080" target="_blank">3584080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30478215">
<a name="30478215"></a>Watt JA, Gomes T, Bronskill SE, et al. Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. <i>CMAJ</i>. 2018;190(47):1376-1383. doi: 10.1503/cmaj.180551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/30478215/pubmed" id="30478215" target="_blank">30478215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19031375">
<a name="19031375"></a>White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. <i>J Med Toxicol</i>. 2008;4(4):238-250. doi:10.1007/BF03161207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/19031375/pubmed" id="19031375" target="_blank">19031375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3977562">
<a name="3977562"></a>White WB, Wong SH. Rapid atrial fibrillation associated with trazodone hydrochloride. <i>Arch Gen Psychiatry</i>. 1985;42(4):424. doi:10.1001/archpsyc.1985.01790270114017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3977562/pubmed" id="3977562" target="_blank">3977562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16389666">
<a name="16389666"></a>Winkler D, Ortner R, Pjrek E, Aschauer H, Kasper S. Trazodone-induced cardiac arrhythmias: a report of two cases. <i>Hum Psychopharmacol</i>. 2006;21(1):61‐62. doi:10.1002/hup.746<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/16389666/pubmed" id="16389666" target="_blank">16389666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35343583">
<a name="35343583"></a>Yilbaş B. Restless legs syndrome due to the use of trazodone: a case report. <i>Turk Psikiyatri Derg</i>. 2022;33(1):70-72. doi:10.5080/u25787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/35343583/pubmed" id="35343583" target="_blank">35343583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29680424">
<a name="29680424"></a>Yi XY, Ni SF, Ghadami MR, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. <i>Sleep Med</i>. 2018;45:25-32. doi:10.1016/j.sleep.2018.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/29680424/pubmed" id="29680424" target="_blank">29680424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19112384">
<a name="19112384"></a>Zavesicka L, Brunovsky M, Horacek J, et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. <i>Neuro Endocrinol Lett</i>. 2008;29(6):895-901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/19112384/pubmed" id="19112384" target="_blank">19112384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3690130">
<a name="3690130"></a>Zmitek A. Trazodone-induced mania. <i>Br J Psychiatry.</i> 1987;151:274-275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/trazodone-drug-information/abstract-text/3690130/pubmed" id="3690130" target="_blank">3690130</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10013 Version 635.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
